Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aclarion, Inc. - Warrant (NQ: ACONW )

0.0601 -0.0114 (-15.94%)
Streaming Delayed Price Updated: 3:32 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,999
Open 0.0603
Bid (Size) 0.0568 (20)
Ask (Size) 0.0790 (4)
Prev. Close 0.0715
Today's Range 0.0601 - 0.0790
52wk Range 0.0101 - 0.2446
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st
Via ACCESSWIRE
Aclarion to Present at Third Annual Winter Wonderland - Best Ideas Virtual Investor Conference on February 21st - 24th, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire

Performance

YTD
+135.69%
+135.69%
1 Month
+71.71%
+71.71%
3 Month
+97.05%
+97.05%
6 Month
+97.70%
+97.70%
1 Year
+67.41%
+67.41%

More News

Read More
Aclarion, Inc. Releases Updated Investor Presentation In Connection with Appearance at LD Micro Main Event XV
Via ACCESSWIRE
Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor
Via ACCESSWIRE
Aclarion Announces Participation at the NASS 37th Annual Meeting
Via ACCESSWIRE
John Keller M.D. to Join Aclarion as a Key Opinion Leader Surgeon Advisor
Via ACCESSWIRE
Nociscan Selected for Inclusion in Pivotal National Institutes of Health (NIH) Study for Low Back Pain
Via ACCESSWIRE
Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan
Via ACCESSWIRE
Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan
From Aclarion Inc.
Via AccessWire
Aclarion to Present 2-year Follow Up Data on Pivotal Clinical Trial Linking Nociscan to Better Surgical Outcomes for Discogenic Low Back Pain
From Aclarion Inc.
Via AccessWire
Aclarion, Inc. Announces Closing of $9.4 Million Initial Public Offering
From Aclarion Inc.
Via AccessWire
Topics Artificial Intelligence Regulatory Compliance
Exposures Artificial Intelligence Legal Regulatory
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.